Cargando…
AB51. PDE5 expression in the prostate: where is it really?
PDE5 inhibitor Tadalafil has been approved for the treatment of BPH symptoms, but where PDE5 is expressed in the prostate remains a mystery. In the literature five studies have reported immunolocalization of PDE5 in the prostate. Uckert et al. concluded that PDE5 is mainly expressed in the glandular...
Autor principal: | Lin, Ching-Shwun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708461/ http://dx.doi.org/10.3978/j.issn.2223-4683.2014.s051 |
Ejemplares similares
-
AB041. Evolution of PDE5 inhibitors in Korea
por: Moon, Du Geon
Publicado: (2015) -
AB020. Penile rehabilitation with PDE5 inhibitors in men following radical prostatectomy
por: Jiann, Bang-Ping
Publicado: (2015) -
AB045. Therapeutic potential of Icariin in combination with PDE5 inhibitor on penile atrophy and erectile dysfunction in a rat model of post-prostatectomy
por: Xu, Yongde
Publicado: (2018) -
AB044. Initial analysis of PDE5i and visual-auditory sexual stimulation Rigiscan plus detection results of 1,896 cases in outpatients
por: Gao, Bing, et al.
Publicado: (2015) -
AB012. Brachytherapy for localized prostate cancer
por: Xu, Yong, et al.
Publicado: (2016)